Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 21, 2015, Pages 2353-2360

  Sparano, Joseph A ^a   Zhao, Fengmin ^b   Martino, Silvana ^c   Ligibel, Jennifer A ^b   Perez, Edith A ^d   Saphner, Tom ^e   Wolff, Antonio C ^f   Sledge, George W ^g   Wood, William C ^h   Davidson, Nancy E ⁱ  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e Vince Lombardi Cancer Center ^*  (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; BLACK PERSON; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FACTORIAL DESIGN; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DRUG ADMINISTRATION; ETHNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASM STAGING; OBESITY; PACLITAXEL; TAXOIDS;

EID: 84939867623     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.9271     Document Type: Article

References (46)

1. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
2. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
3. Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432-444, 2012
4. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
5. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996
6. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005
7. Albain KS, Barlow WE, Ravdin PM, et al: Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:2055-2063, 2009
8. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
9. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005
10. Sparano JA, Wang M, Zhao F, et al: Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118:5937-5946, 2012
11. Sparano JA, Wang M, Zhao F, et al: Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406-414, 2012
12. Martín M, Rodríguez-Lescure A, Ruiz A, et al: Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805-814, 2008
13. Martin M, Ruiz A, Ruiz Borrego M, et al: Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study. J Clin Oncol 31:2593-2599, 2013
14. Carlson RW, Allred DC, Anderson BO, et al: Invasive breast cancer. J Natl Compr Canc Netw 9:136-222, 2011
15. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
16. Davies C, Godwin J, Gray R, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378:771-784, 2011
17. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013
18. Goss PE, Ingle JN, Pater JL, et al: Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26:1948-1955, 2008
19. Jin H, Tu D, Zhao N, et al: Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: Analyses adjusting for treatment crossover. J Clin Oncol 30:718-721, 2012
20. Dignam JJ, Dukic V, Anderson SJ, et al: Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 116:595-602, 2009
21. Sestak I, Dowsett M, Zabaglo L, et al: Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105:1504-1511, 2013
22. Niraula S, Ocana A, Ennis M, et al: Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: A meta-analysis. Breast Cancer Res Treat 134:769-781, 2012
23. Pan H, Gray RG: Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials. J Clin Oncol 32:5s, 2014 (suppl 15s; abstr 503)
24. Lunardi G, Del Mastro L, Bighin C, et al: Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment. J Clin Oncol 29:48s, 2011 (suppl; abstr 515)
25. Goodwin PJ, Ennis M, Bahl M, et al: High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 114:517-525, 2009
26. Irwin ML, Duggan C, Wang CY, et al: Fasting C-peptide levels and death resulting from all causes and breast cancer: The health, eating, activity, and lifestyle study. J Clin Oncol 29:47-53, 2011
27. Nelson ER, Wardell SE, Jasper JS, et al: 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094-1098, 2013
28. Wu Q, Ishikawa T, Sirianni R, et al: 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth Cell Rep 5:637-645, 2013
29. Iyengar NM, Hudis CA, Dannenberg AJ: Obesity and inflammation: New insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book 46-51, 2013
30. Simpson ER, Brown KA: Minireview: Obesity and breast cancer: A tale of inflammation and dysregulated metabolism. Mol Endocrinol 27:715-725, 2013
31. Jain R, Strickler HD, Fine E, et al: Clinical studies examining the impact of obesity on breast cancer risk and prognosis. J Mammary Gland Biol Neoplasia 18:257-266, 2013
32. Ligibel JA, Alfano CM, Courneya KS, et al: American Society of Clinical Oncology position statement on obesity and cancer. J Clin Oncol 32:3568-3574, 2014
33. Ligibel JA, Strickler HD: Obesity and its impact on breast cancer: Tumor incidence, recurrence, survival, and possible interventions. Am Soc Clin Oncol Educ Book 52-59, 2013
34. Menashe I, Anderson WF, Jatoi I, et al: Underlying causes of the black-white racial disparity in breast cancer mortality: A population-based analysis. J Natl Cancer Inst 101:993-1000, 2009
35. Newman LA, Mason J, Cote D, et al: African-American ethnicity, socioeconomic status, and breast cancer survival: A meta-analysis of 14 studies involving over 10,000 African-American and 40,000 white American patients with carcinoma of the breast. Cancer 94:2844-2854, 2002
36. Albain KS, Unger JM, Crowley JJ, et al: Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101:984-992, 2009
37. Bach PB, Schrag D, Brawley OW, et al: Survival of blacks and whites after a cancer diagnosis. JAMA 287:2106-2113, 2002
38. Joslyn SA, West MM: Racial differences in breast carcinoma survival. Cancer 88:114-123, 2000
39. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
40. Hershman D, McBride R, Jacobson JS, et al: Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23:6639-6646, 2005
41. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003
42. Tammemagi CM, Nerenz D, Neslund-Dudas C, et al: Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294:1765-1772, 2005
43. Bhargava A, Du XL: Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer 115:2999-3008, 2009
44. Schneider EC, Zaslavsky AM, Epstein AM: Racial disparities in the quality of care for enrollees in medicare managed care. JAMA 287:1288-1294, 2002
45. Shavers VL, Brown ML: Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94:334-357, 2002
46. Lu Y, Ma H, Malone KE, et al: Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol 29:3358-3365, 2011